Effect of amiodarone dose on the risk of permanent pacemaker insertion

PACE - Pacing and Clinical Electrophysiology

Volumn 27, Issue 11, 2004, Pages 1519-1525

  Essebag, Vidal ^a,c   Hadjis, Tom ^b   Platt, Robert W ^c   Abrahamowicz, Michal ^b,c   Pilote, Louise ^b,c,d  

^a HARVARD UNIVERSITY   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Amiodarone; Antiarrhythmia agents; Fibrillation; Pacemakers

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; SOTALOL; VERAPAMIL;

AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CANADA; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART MUSCLE CONDUCTION DISTURBANCE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCRIPTION; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SINUS NODE DISEASE; TIME;

AGE FACTORS; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BRADYCARDIA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART CONDUCTION SYSTEM; HUMANS; MALE; MYOCARDIAL INFARCTION; PACEMAKER, ARTIFICIAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SINOATRIAL NODE; TIME FACTORS;

EID: 9444249840     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2004.00670.x     Document Type: Article

References (24)

1. Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: Clinical implications. J Am Coll Cardiol 2001; 37:371-378.
2. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38:1231-1266.
3. Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42:20-29.
4. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl Med 2000; 342:913-920.
5. Letelier LM, Udol K, Ena J, et al. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: A meta-analysis. Arch Intern Med 2003; 163:777-785.
6. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. Am J Cardiol 2003; 91:15D-26D.
7. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-1833.
8. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-1840.
9. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41:1690-1698.
10. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomized trial. Lancet 2000; 356:1789-1794.
11. Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1897; 127:281-284.
12. Essebag V, Hadjis T, Platt RW, et al. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol 2003; 41:249-254.
13. Pilote L, Lavoie F, Ho V, et al. Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995. CMaj 2000; 163:31-36.
14. i 1998, pp.1235-1247.
15. Vacek PM. Assessing the effect of intensity when exposure varies over time. Stat Med 1997; 16:505-513.
16. Leffondre K, Abrahamowicz M, Siemiatycki J, et al. Modeling smoking history: A comparison of different approaches. Am J Epidemiol 2002; 156:813-823.
17. Bartlett-Esquilant G. Patterns of benzodiazepine use and risk of injury in the elderly. Montreal: McGill University, 2000.
18. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999; 20:145-157.
19. Quantin C, Abrahamowicz M, Moreau T, et al. Variation over time of the effects of prognostic factors in a population-based study of colon cancer; Comparison of statistical models. Am J Epidemiol 1999; 150:1188-1200.
20. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002; 144:597-607.
21. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48:999-1009.
22. Miller E, Blatman B, Einarson TR. A survey of population-based drug databases in Canada. CMAJ 1996; 154:1855-1864.
23. Levy AR, Tamblyn RM, Fitchett D, et al. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol 1999; 15:1277-1282.
24. Tamblyn R, Reid T, Mayo N, et al. Using medical services claims to assess injuries in the elderly: Sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000; 53:183-194.